Articles
Cemiplimab-rwlc (Libtayo), a new PD-1 inhibitor, has transformed the treatment of advanced cutaneous squamous-cell carcinoma (CSCC), significantly extending survival for patients.
By William King
According to results of the phase 3 multinational ADAURA clinical trial, treatment with osimertinib in the adjuvant setting significantly improves disease-free survival in patients with localized non–small-cell lung cancer (NSCLC) with EGFR mutation.
Amina Ahmed, MD, Paula Anastasia, RN, MN, AOCN and Ali McBride, PharmD, describe their experiences in the use of niraparib, olaparib and nucaparib as first-line maintenance therapy in Ovarian Cancer.
This supplement reviews outcomes from several key trials, examines the use of PARP inhibitors and other emerging treatments, and discusses several changes recently made to treatment recommendations from NCCN and ASCO and how those changes can be incorporated into clinical practice.
Amina Ahmed, MD, Paula Anastasia, RN, MN, AOCN, and Ali McBride, PharmD, discuss the relative benefits and risks of maintenance therapy in ovarian cancer with bevacizumab versus a PARP inhibitor.
By Phoebe Starr
The addition of the checkpoint inhibitor atezolizumab (Tecentriq) to the 2 targeted therapies—the BRAF inhibitor vemurafenib (Zelboraf) and the MEK inhibitor cobimetinib (Cotellic)—improved progression-free survival (PFS) and the duration of responses compared with the 2 targeted therapies plus placebo in patients with newly diagnosed advanced melanoma and BRAF V600E/K mutation, according to the phase 3 IMspire150 clinical trial.
By Wayne Kuznar
Tumors with KRAS mutation are notoriously difficult to treat. Early data presented at the 2020 American Association for Cancer Research virtual annual meeting suggest 2 new routes for the treatment of cancers with KRAS mutation, including (1) the combination of a RAF/MEK inhibitor and a FAK inhibitor, and (2) the use of onvansertib, an investigational competitive inhibitor of the PLK1 enzyme, together with chemotherapy.
Amina Ahmed, MD, Paula Anastasia, RN, MN, AOCN, and Ali McBride, PharmD, deliberate on results from recent clinical trials showing the improvement in progression-free survival after first-line maintenance therapy with PARP inhibitors in patients with ovarian cancer, regardless of HRD status. The experts consider the impact of these data on providing improved treatment options for these patients.
In a phase 2 study of women with recurrent platinum-sensitive ovarian cancer, safety and efficacy end points favored the combination of niraparib and bevacizumab over niraparib monotherapy.
New study findings represent a significant advance for women with BRCA-related relapsed ovarian cancer responding to platinum-based chemotherapy.